S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
One year after buying a failed bank, New York Community Bancorp is struggling
Dell, NetApp rise; Ginkgo Bioworks, New York Community Bancorp fall, Friday, 3/1/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
China pledges to increase opportunities for foreign companies as it seeks to boost its economy
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches

Kooth (KOO) Competitors

GBX 290
+10.00 (+3.57%)
(As of 03/1/2024 ET)

KOO vs. RENX, ETX, 4BB, BVC, SCLP, DXRX, REDX, ANCR, FARN, and CEL

Should you be buying Kooth stock or one of its competitors? The main competitors of Kooth include Renalytix (RENX), e-therapeutics (ETX), 4basebio (4BB), BATM Advanced Communications (BVC), Scancell (SCLP), Diaceutics (DXRX), Redx Pharma (REDX), Animalcare Group (ANCR), Faron Pharmaceuticals Oy (FARN), and Celadon Pharmaceuticals (CEL). These companies are all part of the "medical" sector.

Kooth vs.

Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, community ranking, analyst recommendations and risk.

Renalytix received 18 more outperform votes than Kooth when rated by MarketBeat users. However, 83.33% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote.

CompanyUnderperformOutperform
KoothOutperform Votes
5
83.33%
Underperform Votes
1
16.67%
RenalytixOutperform Votes
23
74.19%
Underperform Votes
8
25.81%

In the previous week, Kooth had 2 more articles in the media than Renalytix. MarketBeat recorded 3 mentions for Kooth and 1 mentions for Renalytix. Renalytix's average media sentiment score of 0.00 beat Kooth's score of -0.43 indicating that Renalytix is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kooth
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Renalytix
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

78.4% of Kooth shares are held by institutional investors. Comparatively, 10.2% of Renalytix shares are held by institutional investors. 11.3% of Kooth shares are held by company insiders. Comparatively, 41.3% of Renalytix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Kooth has higher revenue and earnings than Renalytix. Kooth is trading at a lower price-to-earnings ratio than Renalytix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kooth£22.76M4.63N/A-£0.03-9,666.67
Renalytix£2.41M16.59-£41.85M-£0.36-111.11

Kooth has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 1.75, meaning that its share price is 75% more volatile than the S&P 500.

Kooth currently has a consensus price target of GBX 402.50, indicating a potential upside of 38.79%. Given Kooth's higher possible upside, equities analysts plainly believe Kooth is more favorable than Renalytix.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kooth
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Renalytix
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Renalytix has a net margin of 0.00% compared to Kooth's net margin of -3.95%. Kooth's return on equity of -8.45% beat Renalytix's return on equity.

Company Net Margins Return on Equity Return on Assets
Kooth-3.95% -8.45% -8.37%
Renalytix N/A -651.40%-88.32%

Summary

Kooth beats Renalytix on 9 of the 16 factors compared between the two stocks.


Get Kooth News Delivered to You Automatically

Sign up to receive the latest news and ratings for KOO and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KOO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KOO vs. The Competition

MetricKoothHealth Information Services IndustryMedical SectorLON Exchange
Market Cap£105.44M£243.57M£5.04B£1.45B
Dividend YieldN/A6.11%2.81%11.93%
P/E Ratio-9,666.67467.34268.691,848.27
Price / Sales4.631,073.933,024.12422,854.18
Price / Cash5.4242.6298.1934.31
Price / Book9.068.124.602.62
Net IncomeN/A-£6.17M£115.00M£172.06M
7 Day Performance12.40%2.12%5.65%0.32%
1 Month Performance5.42%2.94%11.14%5.02%
1 Year Performance69.29%-1.46%14.00%12.92%

Kooth Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RENX
Renalytix
0 of 5 stars
GBX 28
-16.4%
N/A-72.7%£27.98M£2.89M-70.00102Gap Up
ETX
e-therapeutics
0 of 5 stars
GBX 16.55
+0.5%
N/A-14.6%£96.71M£295,000.00-827.5034Gap Up
4BB
4basebio
0 of 5 stars
GBX 725
flat
N/A+27.1%£92.87M£311,000.00-1,421.5778Gap Up
BVC
BATM Advanced Communications
0 of 5 stars
GBX 20.60
+0.5%
N/A-11.6%£89.86M£118.78M2,800.00949News Coverage
SCLP
Scancell
0 of 5 stars
GBX 11.25
flat
N/A-43.2%£104.38M£5.27M-1,125.0051Gap Up
DXRX
Diaceutics
1.5228 of 5 stars
GBX 98.50
flat
GBX 150
+52.3%
-18.1%£83.41M£21.90M10,500.00151
REDX
Redx Pharma
0 of 5 stars
GBX 19.50
flat
N/A-53.3%£75.85M£4.20M-195.0065Gap Down
ANCR
Animalcare Group
0 of 5 stars
GBX 194
flat
N/A+28.3%£116.61M£70.04M9,700.00220Gap Up
FARN
Faron Pharmaceuticals Oy
0 of 5 stars
GBX 170
+1.2%
N/A-53.6%£116.98M£-725,000.00-404.7640Gap Down
High Trading Volume
CEL
Celadon Pharmaceuticals
0 of 5 stars
GBX 112.50
flat
GBX 222.50
+97.8%
+98.1%£72.24M£11,258.00-865.3824Gap Up

Related Companies and Tools

This page (LON:KOO) was last updated on 3/2/2024 by MarketBeat.com Staff